Long‐term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS

Stephen A. Goutman, Morton B. Brown, Jonathan D. Glass, Nicholas M. Boulis, Karl Johe, Tom Hazel, Merit Cudkowicz, Nazem Atassi, Lawrence F. Borges, Parag G. Patil, Stacey A. Sakowski, Eva L. FeldmanAnnals 2018 · DOI

Abstract

Comparison of Ph1/2 studies to historical datasets revealed significantly improved survival and function using ALS/SURV versus PRO-ACT controls. While results are encouraging, comparison against historical populations demonstrate limitations in noncontrolled studies. These findings support continued evaluation of HSSC transplantation in ALS, support the benefit of control populations, and enable necessary power calculations to design a randomized, sham surgery-controlled efficacy study.
BibTeX
@article{goutman2018longterm,
  author = {Stephen A. Goutman and Morton B. Brown and Jonathan D. Glass and Nicholas M. Boulis and Karl Johe and Tom Hazel and Merit Cudkowicz and Nazem Atassi and Lawrence F. Borges and Parag G. Patil and Stacey A. Sakowski and Eva L. Feldman},
  title = {{Long‐term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS}},
  journal = {Annals},
  year = {2018},
  doi = {10.1002/acn3.567},
}

Loading related content...

Figure